Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11995MR)

This product GTTS-WQ11995MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11995MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10915MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ10895MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ258MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ1489MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ4242MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ2149MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ11154MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ3121MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW